Key message:
In this single-center, phase Ib/II study, the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) was evaluated in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study demonstrated an objective response rate of 54%, with complete responses achieved in 38% of patients. ViPOR demonstrated high efficacy in germinal center B-cell (GCB) tumors with MYC and BCL2 translocations, resulting in a 2-year progression-free survival rate of 47% in these patients compared with 8% in patients without translocations. Complete responses were particularly observed in patients with non-GCB DLBCL and high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements (HGBCL-DH-BCL2). The 2-year progression-free survival and overall survival were 34% and 36%, respectively. Additionally, among patients previously treated with CAR T-cell therapy, ViPOR was associated with a 2-year progression-free survival of 30%.
Safety data revealed grade 3 or 4 neutropenia, thrombocytopenia, and anemia in 24%, 23%, and 7% of cycles, respectively. In addition, grade 3 or higher hypokalemia occurred in 28% of patients, highlighting the need for aggressive monitoring and electrolyte replacement. The promising efficacy of ViPOR in patients with relapsed or refractory non-GCB DLBCL and HGBCL-DH-BCL2 suggests the need for larger validation studies.
SUMMARY
BACKGROUND
The identification of oncogenic mutations in diffuse large B-cell lymphoma (DLBCL) has led to the development of drugs targeting major survival pathways, but it remains unknown whether targeting multiple survival pathways can be curative in DLBCL.
METHODS
We conducted a single-center, phase 1b-2 study of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed or refractory DLBCL. Phase 1b, which included patients with DLBCL and indolent lymphomas, evaluated four dose levels of venetoclax to determine the recommended dose for phase 2, with fixed doses of the other four drugs. A phase 2 extension was performed in patients with germinal center B-cell (GCB) and non-GCB DLBCL. ViPOR was administered every 21 days for six cycles.
RESULTS
In a phase 1b study of 20 patients (10 with DLBCL), a single dose-limiting toxicity of grade 3 intracranial hemorrhage was observed, leading to venetoclax 800 mg being the recommended dose for phase 2. Phase 2 enrolled 40 patients with DLBCL. Toxicities observed in all patients included grade 3 or 4 neutropenia (in 24% of cycles), thrombocytopenia (in 23%), anemia (in 7%), and febrile neutropenia (in 1%). Objective responses were observed in 54% of 48 evaluable patients with DLBCL, and complete responses were observed in 38%; Complete responses were observed exclusively in patients with non-GCB DLBCL and high-grade B-cell lymphoma with MYC and BCL2 or BCL6 (or both) rearrangements. Circulating tumor DNA was undetectable in 33% of patients at the end of ViPOR therapy. At a median follow-up of 40 months, the 2-year progression-free survival and overall survival rates were 34% (95% confidence interval (CI) 21 to 47) and 36% (95% CI 23 to 49), respectively.
CONCLUSIONS
ViPOR treatment was associated with durable remission in patients with specific molecular subtypes of DLBCL and predominantly reversible adverse events.
Recommendations
Christopher Melanie, Rahul Lakhotia and others.
DOI: 10.1056/NEJMoa2401532
Link: https://www.nejm.org/doi/10.1056/NEJMoa2401532
Fountain
BioPress
Meta is preparing an update that will improve organization in WhatsApp WhatsApp wants users to…
Hansi Flick had no hesitation: what works, the less you touch it, the better. Dani…
The victory was a vengeance for Johnny Depp, who was deprived of a precedent-setting lawsuit…
Different types of love manifest differently in the brain, which responds most strongly to the…
The World Health Organization (WHO) said on Tuesday that recommends that masks be used only…
Corte Inglés on Portal de l'Angel in Barcelona will close this Saturday, August 31, two…